Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis Clear all
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 21, 2026, 4:16 PM EDT
Withdrawn No phase listed Observational

Diesel Exhaust Particles and Leukotriene Production

NCT00915447
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 4:16 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Viral Mucosal Reprogramming

NCT05331170
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cat Allergy, Healthy
Interventions
Research Grade RG-RV
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

NCT00854360
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hayfever
Interventions
Beclomethasone dipropionate HFA Nasal Aerosol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Mission Viejo, California • San Diego, California • Colorado Springs, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
43
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays

NCT00279916
View directory record Official record
Conditions
Otitis Media, Serous, Negative Middle Ear Pressure, Rhinitis, Otitis Media With Effusion, Otitis Media, Secretory
Interventions
Triamcinolone acetonide nasal spray, Placebo nasal spray
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years to 100 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jul 21, 2026, 4:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 4:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome

NCT00732680
View directory record Official record
Conditions
Empty Nose Syndrome, Atrophic Rhinitis
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02631551
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
37
States / cities
Mission Viejo, California • San Diego, California • San Jose, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 21, 2026, 4:16 PM EDT
Terminated Not applicable Interventional

Treatment of Rhinitis With Intranasal Vitamin E

NCT00281307
View directory record Official record
Conditions
Rhinitis
Interventions
RRR-alpha-tocopherol 1,000 IU/mL
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Erenumab for Idiosyncratic Facial Pain

NCT04249427
View directory record Official record
Conditions
Facial Pain, Rhinosinusitis
Interventions
Erenumab Prefilled Syringe, Placebo
Drug · Other
Lead sponsor
David Jang, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 21, 2026, 4:16 PM EDT
Terminated Phase 1 Interventional

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

NCT00630461
View directory record Official record
Conditions
Mild Allergic Rhinitis, Mild Allergic Rhinitis With Mild Asthma
Interventions
Clinical Center Reference Endotoxin
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Jul 21, 2026, 4:16 PM EDT
Not listed Phase 4 Interventional

Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis

NCT00825656
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Sinol or Sinol-M nasal spray
Drug
Lead sponsor
Strategic Biosciences
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Not applicable Interventional

NEUROMARK Randomized Controlled Trial

NCT06128200
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
NEUROMARK System, Sham NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Homewood, Alabama • Opelika, Alabama • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

NCT05591989
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • California City, California • Temecula, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

NCT00745849
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
esomeprazole, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 21, 2026, 4:16 PM EDT
Not listed No phase listed Observational

Effect of Montelukast on Basophils, In-vitro

NCT00710450
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 21, 2026, 4:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717
View directory record Official record
Conditions
Allergic Rhinitis Due to Cat Allergy
Interventions
REGN1908-1909, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 21, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

NCT00578929
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
6 Years to 11 Years
Enrollment
2,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kenilworth, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 21, 2026, 4:16 PM EDT